Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6789510 | 0.91 | HPGD (0.51) | KMT2AMEN1HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL1287360 | 0.84 | ALDH1A1 (0.51) | KMT2AMEN1HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL13825606 | 0.80 | KMT2A (0.70) | KMT2AMEN1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL16140981 | 0.74 | KMT2A (1.00) | KMT2AMEN1HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL13412657 | 0.73 | KMT2A (0.51) | KMT2AMEN1HTTALDH1A1KDM4E | |
| SCHEMBL8336245 | 0.72 | GAA (0.55) | KMT2AMEN1HTTALDH1A1KDM4E | |
| SCHEMBL9682135 | 0.72 | GAA (0.58) | KMT2AMEN1HTTALDH1A1KDM4E | |
| SCHEMBL6234624 | 0.72 | GAA (0.58) | KMT2AMEN1HTTALDH1A1KDM4E | |
| SCHEMBL2901212 | 0.71 | GAA (0.71) | KMT2AMEN1HTTALDH1A1KDM4E | |
| SCHEMBL29196492 | 0.71 | POLB (0.61) | KMT2AMEN1HTTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776963-B2 | Small molecule CD4 mimetics and uses thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-10-03 | — | — | US | disclosed |
| US-20120122834-A1 | SMALL MOLECULE CD4 MIMETICS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122834-A1 | SMALL MOLECULE CD4 MIMETICS AND USES THEREOF | CD4, CCR1, RORC | KMT2A 2177/4885MEN1 4455/4885HTT 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.